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EDITORIAL
Extending the "Lower is Better" Principle to Japanese and Possibly Other Asian Populations
Article, see p 1997 C ardiovascular disease (CVD) is well known as a leading cause of death around the world, accounting for ≈30% of all deaths. Controlling hyperlipidemia, especially high low-density lipoprotein cholesterol (LDL-C), is widely recognized as an important countermeasure against CVD.
Notable progress in combating high LDL-C began with 2 ground-breaking events in the 1970s: the discovery of the LDL receptor by Brown and Goldstein, 1 which provides a theoretical basis for understanding the mechanism of high LDL-C, and the discovery by Endo et al 2 of statins, which increase the synthesis of LDL receptors and reduce LDL-C. From 2005, the Cholesterol Treatment Trialists' Collaboration (CTTC) began to provide a focused meta-analysis of statin-driven inhibition of cardiovascular events. A CTT meta-analysis of large-scale randomized, controlled studies using statins in 2010 showed significant reductions in cardiovascular events with statin therapy (a decrease of 1 mmol/L in LDL-C was associated with a 22% reduction in cardiovascular events) and also demonstrated that high-dose statin therapy provided greater benefit than moderate-dose therapy. 3 Based on these data, the 2013 American College of Cardiology/American Heart Association guidelines 4 emphasized the importance of high-dose statin therapy in high-risk groups to reduce cardiovascular risk.
However, almost all of this evidence originated in Western countries, based primarily on data from white subjects. There is a possibility that the response to statin therapy differs among different regions or in different ethnicities. If we adhere strictly to the principles of evidence-based medicine, these data cannot be applied to nonwhite races or ethnic groups without supporting research. For example, Japan and South Korea have historically shown low levels of LDL-C, whereas hypertension is very common. As a result, these populations show a consistent trend toward high incidence of stroke, which is closely related to hypertension, and relatively low incidence of ischemic heart disease (IHD, also known as coronary artery disease), which is closely related to LDL-C. Data from the 2017 World Health Organization report show an age-adjusted IHD death rate of 31.2/100 000 person-yr in Japan, 34.7 in South Korea, and 80.5 in the United States; the corresponding figures for stroke are 36.7 in Japan, 65.1 in South Korea, and 25.4 in the United States. 5 These circumstances have naturally led to a strong emphasis on the treatment of hypertension in Japan and South Korea. However, we are now witnessing a recent gradual trend toward lower incidence of stroke and higher incidence of IHD even in East Asian countries.
There were other data to show lower incidence of IHD in East Asian countries. In the 1960s, data from the Seven Countries Study showed the death rate from coronary heart disease to be 5 times lower in Japan than in the United States. 6 However, in recent years a combination of economic recovery and a shift toward more West- ernized lifestyle and habits have been accompanied by a gradual increase in serum cholesterol in the Japanese population. 7 Meanwhile, a population-based approach to hypercholesterolemia in the United States has been accompanied by a decrease in US cholesterol levels and a reduced death rate from myocardial infarction. These changes have narrowed the difference in the IHD death rate between Japan and the United States; for example, according to the 2017 World Health Organization report, the death rate from IHD in the United States is now 3.8 times greater than in Japan.
5 Though the IHD death rate is still low in Japan when compared with Western countries, CVD death makes up 29% of all-cause death in Japan and 25% in South Korea and CVD ranks second in both countries as a cause of death. 5 We expect that the prevention of CVD will become more important as a health measure in Japan, South Korea, and a number of other Asian countries in the near future.
The MEGA study (The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese), the first large-scale prevention study to be conducted in Asia, showed that cardiovascular events were significantly reduced by statins in primary prevention. 8 For the statin therapy used in the MEGA study (10 mg pravastatin), the 5-year number needed to treat to avoid 1 additional event was 119. Although this particular statin regimen could not be considered potent treatment, the study meaningfully demonstrated that statin therapy can also be effective even in a low-risk group. Statin therapy may be more effective in Japanese, as evidenced by the 44% reduction rate in cardiovascular events in the MEGA study versus 22% in CTT meta-analysis per 1 mmol/L reduction in LDL-C.
Secondary prevention has proven to be of considerable importance in Japan, too. The J-LIT study (The Japan Lipid Intervention Trial) in Japan showed that the incidence of cardiovascular events was ≈5-fold higher in the secondary prevention group 9 than in the primary prevention group 10 (4.45/1000 person-yr versus 0.91/1000 person-yr). Therefore, as in Western countries, primary prevention is important for reducing CVD events, but secondary prevention is more effective and more critical. However, up to this point almost all secondary prevention trials performed in Japan have studied imaging surrogates rather than clinical events. Though some event prevention studies have been conducted, they were unable to show significant effects because they involved a limited number of subjects or were not well-controlled comparative studies. Because of the lack of evidence for further reduction of cardiovascular events with higher doses of statins and fear of potential side effects such as muscle pain, liver dysfunction, and increased risk of intracranial hemorrhage and cancer, low doses of statins (eg, 10 mg of pravastatin and 5 mg of atorvastatin) have been used widely in Japan.
In this issue of Circulation, Taguchi et al 11 report the results of the REAL-CAD study (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease), a largescale well performed secondary prevention study in 13 054 patients in Japan. This study evaluated the effects of statin dose on the reduction in cardiovascular events, using a study design similar to the previously reported TNT study (The Treating to New Targets). 12 This study reported that the use of high-dose (4 mg) pitavastatin to lower LDL-C (to 73.7 mg/dL at 6 months) was more effective than the use of low-dose (1 mg) pitavastatin in reducing cardiovascular events without increasing serious adverse events such as intracranial hemorrhage. This study is meaningful because, as emphasized by the authors, this is the first "more versus less statin" study conducted in Asia to prove the efficacy of higher dose statin therapy. However, it is also possible to interpret the authors' findings as a therapeutic strategy that focuses on LDL-C "lower is better" rather than statin "more versus less" because the findings from IMPROVE-IT (The Improved Reduction of Outcomes: Vytorin Efficacy International Trial) 13 and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) 14 studies using nonstatin drugs concomitantly with the statin demonstrated dose-dependent efficacy and equivalence.
The study by Taguchi et al 11 is important for 2 reasons. First, it shows that the efficacy of LDL-C lowering, which up to this point had been demonstrated primarily in Western countries, also applies in a specifically Japanese subset of the Asian population. Second, it suggests the importance of providing intensive statin therapy in accordance with risk, even in Asian patients.
Japanese treatment guidelines recommend a therapeutic target of LDL-C <100 mg/dL for secondary prevention. However, the publication of this study suggests that in secondary prevention it may be clinically important to lower LDL-C not only to the target of <100 mg/ dL, but even further, to ≈75 mg/dL, and there is some evidence for considering the target level of <70 mg/dL endorsed by Western guidelines. Of further importance, it is highly likely that these findings will also apply in South Korea and other Asian countries where, like Japan, IHD risk is lower than in the West. In addition, a number of Asians live in Europe and the United States; in terms of evidence-based medicine, the findings described by Taguchi et al may apply to such "overseas" Asians as well. From that perspective, this study has additional value for providing an element of universal evidence that can be used globally, and perhaps bring us a small step closer to universal evidence-based medicine. Real-world data from Japan show that pitavastatin 4 mg is being used in only 3% of patients with acute coronary syndrome and 2% of patients with coronary heart disease. 15 This may be attributed in part to concern about adverse drug reactions such as intracranial hemorrhage in relation to high-dose statin or intensive LDL-C-lowering therapy. Some Japanese general physicians prescribe very low dose statins such as 5 mg atorvastatin, 2.5 mg rosuvastatin, or 5 mg pravastatin, because they are concerned about intracranial hemorrhage, of which the incidence has been reported to be high in Japan and other Asian populations, particularly in the subset with low cholesterol level. The REAL-CAD study showed a higher incidence of mild muscle pain in the 4-mg group, but no major differences in serious adverse events including intracranial hemorrhage between the 2 groups. These findings suggest a favorable risk-benefit relationship for aggressive lipid lowering in high-risk patients, even in Japan, and perhaps in other similarly low-risk countries. In the future, we favor recommendation of the 4-mg pitavastatin dose for secondary prevention. We look forward to seeing further discussion of treatment strategies, including from the perspective of economic efficiency. 
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